Update on Youth-Onset Type 2 Diabetes

Gandica, Rachelle; Zeitler, Phil

doi:10.1016/j.yapd.2016.04.013

Cited by 7 publications

(1 citation statement)

References 37 publications

(67 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The failure of the current therapeutic agents in halting the deterioration of T2DM in children was also observed in youth with recently diagnosed T2DM [19, 37]. The TODAY trial found that metformin monotherapy had higher failure rates compared to the treatment of metformin and rosiglitazone [38], but no comparisons were made with insulin treatment in the TODAY cohort. The TODAY study also demonstrated nearly 50% of glycemic failure in those receiving metformin monotherapy treatment [20, 38]; in comparison, our failure rate was higher (65%).…”

Section: Discussionmentioning

confidence: 99%

Glycemic control and lipid outcomes in children and adolescents with type 2 diabetes

2019

View full text Add to dashboard Cite

Background The incidence of type 2 diabetes (T2DM) in children has increased dramatically. However, limited published information is known about the glycemic control and lipid outcomes in pediatric T2DM outside of clinical trials. Objectives To determine the glycemic control and lipid measure outcomes at one and three- year follow-up in children with T2DM. Methods A retrospective electronic medical record review of children with T2DM at the Children’s Hospital of Alabama over a 12-year period. Results There were 301 patients with a diagnosis of T2DM who had a 1-year follow-up visit, of which 184 also had a 3-year follow-up. Most patients (78%) received either insulin with metformin or insulin alone at diagnosis. At one year, 37% of the cohort achieved ‘optimal glycemic control’ (HbA1C ≤6.5%) and 58% of patients achieved durable glycemic control (HbA1C ≤8%). Optimal glycemic control was seen in 48 patients at 3 years. The patients treated with insulin (alone or in combination with metformin) tended to have higher HbA1C at diagnosis, but had improved lipid and glycemic outcomes at follow-up. The group treated with insulin along with metformin had significant improvements in non-HDL, HDL and TC/HDL ratios. The effects of insulin treatment on glycemic control at 3 years were not statistically significant. Conclusion With the current modality of treatment, only a minority of patients achieve optimal glycemic control at 1 and 3 years of follow-up. Studies are warranted to further elucidate the optimal therapies in the management of pediatric T2DM.

show abstract